A Phase Ib Trial of Neoadjuvant AMG-232 Concurrent with Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Study of AMG-232 with Preoperative Radiotherapy in Subjects with Soft Tissue Sarcoma (STS)
Sponsor: National Institutes of Health NIH
Enrolling: Male and Female Patients
IRB Number: AAAS6693
U.S. Govt. ID: NCT03217266
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the safety of a study drug called AMG 232 given with radiation in patients with soft tissue sarcoma (STS) prior to surgery. The AMG 232 is investigational. It has been tested in other cancers but not yet in sarcoma. AMG 232 has not been tested using the dosing schedule in this study and it has not been tested with radiation therapy. This study tests increasing frequency of AMG 232 doses (2-5 per week) to determine the maximum safe dose, if any, that can be used in combination with radiation therapy. The dose that you receive will depend on when you begin to participate in this study. There will be between 12 to 46 people taking part in this study.
This study is closed
Gary Schwartz, MD
Do You Qualify?
Are you 18 years of age or greater? Yes No
Have you been diagnosed with soft tissue sarcoma? Yes No
Do you have a planned surgery for your tumor? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator